|  |
| --- |
| ***For internal use only:*** |
| *Cancéropôle partner:*  | *Date of receipt:*  | *File number:*  |

**Deadline 2018, October 31th**

***MATWIN*** *is a French nationwide programme that identifies and supports the maturation of oncology research projects up to the preclinical Proof of Concept. The present form should describe your project from a translational point of view. To access MATWIN’s support, the project will first be reviewed by an International Board. For assistance do not hesitate to ask your Technology Transfer Office and/or institutional partner (Cancéropôle, research institution…) or MATWIN.*

**Research Project**

|  |  |
| --- | --- |
| **Title** |  |
| **Acronym** |  |
| **Key words** |  |

**Project Coordinator**

|  |  |
| --- | --- |
| **Title; Name** |  |
| **Position** |  |
| **Lab / Organization** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

**For European project outside France – French established collaborator**

|  |  |
| --- | --- |
| **Title; Name** |  |
| **Position** |  |
| **Lab / Organization** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

**Technology Transfer Office (*for academic team)* / Patent Office (*for start-up)***

|  |  |
| --- | --- |
| **Name** |  |
| **Contact name** |  |
| **Address** |  |
| **E-mail** |  | **Phone / Mobile** |  |

1. **ABSTRACT (400 words MAX - NOT CONFIDENTIAL)**

(Summarize your project as NOT confidential, to allow diffusion to peers without jeopardizing proprietary information). **Only the abstract must be considered as NOT confidential.**

👉 Please, note that your summary must answers the followings and indicate your French established collaboration *(for European project outside France only)*:

1. Application domain

2. Innovative component / Competitive differentiator

3. Objectives

4. Concept

5. Methodology

6. Expected results

7. Impact

1. **INTELLECTUAL PROPERTY**

**Patent 🡪 one table for each patent, filed or granted**

|  |  |
| --- | --- |
| Patent title |  |
| Date of patent filing |  |
| Patent co-owners (institutions) |  |
| PCT number |  |
| Freedom To Operate ? Y/N - Patent officer |  |
| Potential agreement (license) limiting use of IP? Involved parties & type of agreement? |  |

1. **SCIENTIFIC PROJECT (4 PAGES MAX - CONFIDENTIAL)**
* **Context and background**: Describe succinctly the context and the goal to be reached. **(1/2 PAGES MAX)**
* **Current stage of development:** Describe the project’s development stage relative to the goal to be reached **(bullet points)**, including **the essential / relevant data** justifying your claims regarding the mechanism of action, the proof of concept, benchmarking, etc. with **3-4 figures** of the most relevant and differentiating data. **(3 PAGES MAX)**
* **Research and development plan**: List the main steps / workpackages to achieve the final goal **(bullet points) (1/2 PAGES MAX)**

# UNDERTAKING

## Project Leader

*I, undersigned confirm that I (i) completed all sections and that all information given in this form is complete and true, (ii) obtained the agreement of collaborators and institutional contacts for their participation (iii)* ***fully agree with the Charter on rights and duties of MATWIN applicants*** *(included appendix). I authorise the MATWIN society to share my application form for assessment, under confidentiality agreement condition for each person who accesses this as described in MATWIN charter.*

|  |  |
| --- | --- |
| **Name** | **Date and Signature** |
|  |  |

File to be sent to: emmanuel.conseiller@matwin.fr before October 31th 2018

**APPENDIX - IMPORTANT**

**MATWIN Charter**

**Rights and Duties**

MATWIN, a wholly owned subsidiary of UNICANCER group, is the service company supporting the MATWIN Programme which relies on a collaborative process with major pharmaceutical and diagnostic companies and a team of international scientific experts to accelerate research and innovation transfer of early stage innovation in oncology with high transfer potential.

MATWIN, acting like a mutualized projects sourcing platform for industrial partners, is fully committed to increase the international attractiveness of research in oncology and to identify and qualify the projects in order to connect them with the most appropriate/suitable partners willing to support them during their industrial maturation stage.

MATWIN’s operational decisions rely on an International multidisciplinary Board which meets annually (referred to hereinafter as “MATWIN Board”) gathering key opinion leaders in oncology from all Europe and industrial representatives from the MATWIN industrial partners. This committee is responsible for assessing and recommending the submitted projects and after each annual Board meeting, every industrial partner has a prior right to express an interest on developing (or co-developing) projects.

**MATWIN’s duties**

1. **Best practices**

MATWIN undertakes to implement the MATWIN Programme according to the best practices in order to meet the requirements of the technology transfer to the preclinical proof of concept stage.

MATWIN undertakes to make every effort with the support of the major research and care institutions, to:

* + Identify the best projects in oncology from the whole European territory.
	+ Help to structure these projects in accordance with the industrial partners’ requirements.
	+ Shorten as most as possible the period of time between the patent and the transfer in order to accelerate the availability of possible therapeutic innovations.
1. **Applicants visibility**

MATWIN undertakes to give the best visibility to every submitted project in order to reinforce sourcing opportunities.

MATWIN undertakes to raise greater awareness of every submitted project by providing access to the industrial partners represented at the highest level on the MATWIN Board (International Global executive, Early development, drug discovery or oncology position) of all the necessary documents to ease its assessment.

MATWIN undertakes to provide all necessary efforts to facilitate intermediation between submitted projects after their presentation to the MATWIN Board:

* by requesting from the industrial Board members and finance representative invitees (the 'Partners') to indicate a potential prior interest on projects submitted to the MATWIN Board in the prior deadline suggested by MATWIN (usually 30 to 60 days after the Board meeting).
* In case of an interest on one or several projects, MATWIN Partner could mandate the platform to provide a support on coordinating and following the exchanges with the applicants and organisms that own the IP (and/or their legal representatives) until the signature of a potential partnership or transfer agreement regarding the concerned project(s).
1. **Confidentiality**

MATWIN undertakes ensuring confidentiality related to every submitted project by prohibiting internal and external communication of any confidential document without the applicant's prior written approval.

Generally speaking, each actor of the MATWIN programme (MATWIN employees, experts, coaches, members and invited members of the MATWIN Board) undertakes not to publish or disclose under no circumstances the confidential scientific or technical information and datas belonging to the applicants by signing a confidential agreement with MATWIN prior accessing to any of these information.

**The Applicant’s duties**

1. **Best practices and divulgation**

The applicant guarantees the accuracy of scientific data presented all along the MATWIN Programme as well as their origin.

According to MATWIN's confidentiality duties, the applicant undertakes providing all scientific information and datas all along the MATWIN process for an optimal assessment of the project. In case the applicant may refuse to share the expected scientific information and datas, he takes the risk of being excluded from the Programme.

1. **Transparency**

The applicant undertakes keeping MATWIN informed of any discussions that may be initiated as a consequence of the MATWIN programme.

This encompasses:

* Discussions with Technology Transfer structures, industrial and funding partners of MATWIN as a direct consequence of MATWIN’s intermediation,
* Discussions with industrial and funding structures as a consequence of both MATWIN Board labeling and MATWIN Programme feedback.

The applicant undertakes keeping MATWIN informed of any agreement that may be signed as a (direct or indirect) consequence of the MATWIN Programme.

This encompasses:

* Extension of maturation programme agreed with a Technology Transfer Office
* Start-up creation
* Collaboration agreement with industrial partner
* Licensing agreement
* Funding agreement, etc.

The applicant undertakes facilitating the use by MATWIN of such information for advertising on and promoting the MATWIN Programme.

1. **Financial duties**
	1. **Reimbursement of MATWIN Programme costs**

Programme

The French applicants undertake to reimburse the overall cost of the Programme they benefited from in case of any agreement that may be concluded as a direct or indirect consequence of the MATWIN Programme. This encompasses:

* Extension of maturation programme agreed with a Technology Transfer Office
* Funding agreement
* Collaboration or Licensing agreement

The non-French European applicants will have access to a specific support and thus undertake to reimburse the costs of the Programme they benefited from, according to final step reached within the MATWIN process.

The costs associated to MATWIN Programme are as follow :

* MATWIN Board feedback post pitch’s selection : 2000 €
* Coaching alone : 4000 €
* Coaching + MATWIN Board presentation: 8000 €
	1. **Fees for success**

In case of any successes as described previously (funding except extension of maturation programme, collaboration or license agreements), and on top of reimbursement of the MATWIN Programme costs, the applicant (and its Technology Transfer Office when applicable) undertakes to pay success fees to MATWIN.

These success fees will be negotiated between MATWIN and the applicant (and its Technology Transfer Office when applicable) ranging from 2% to 10% of the amount of the funding agreement according to the type and extent of agreement that was concluded (collaboration or licensing agreement, funding agreement, fundraising, etc.). Of course, the MATWIN Programme costs that have already been reimbursed will be deducted from the success fees, which will be negotiated according to every type of generated success.

Pierre FUMOLEAU

MATWIN President

